aTyr Pharma | LIFE - Cash And Equivalent


aTyr Pharma reported $16.16M in Cash and Equivalent for its fiscal quarter ending in June of 2026.





Cash And Equivalent Change Date
Alterity Therapeutics Limited AUD 15.77M 9.56M Jun/2023
Ardelyx USD 31.21M 36.79M Mar/2026
aTyr Pharma USD 16.16M 6.15M Jun/2026
Biogen USD 1.28B 2.1B Jun/2026
Bristol-Myers Squibb USD 8.72B 852M Jun/2026
Cipla INR 10.18B 2.22B Mar/2026
Clal Biotechnology ILS 5.73M 1.71M Dec/2023
Compugen USD 12.43M 78.16M Mar/2026
CSL USD 2.16B 633M Jun/2025
Curis USD 10.14M 10.14M Jun/2025
GlaxoSmithKline GBP 3.44B 292M Mar/2026
Grifols EUR 979.78M 334.84M Dec/2024
Lakefront Biotherapeutics EUR 135.95M 69.15M Jun/2026
Novartis USD 7.62B 739M Jun/2026
Roche Holding CHF 7.55B 579M Jun/2025
United Therapeutics USD 1.8B 523.5M Jun/2026